Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | HTR2B | P41595 | 4/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22283580 | 1.00 | PDE2A (0.41) | PDE2ASCN8ASCN10ASLC6A4HTR2C | |
| SCHEMBL20865577 | 0.88 | PDE2A (0.35) | PDE2AGRIN1GRIN2B | |
| SCHEMBL22283606 | 0.84 | SLC6A4 (0.39) | PDE2ASCN8ASCN10ASLC6A4HTR2C | |
| SCHEMBL22283675 | 0.84 | SLC6A4 (0.39) | PDE2ASCN8ASCN10ASLC6A4HTR2C | |
| SCHEMBL23105269 | 0.81 | SLC6A4 (0.47) | SCN8ASCN10ASLC6A4HTR2CHTR2B | |
| SCHEMBL30700642 | 0.81 | SLC6A4 (0.47) | SCN8ASCN10ASLC6A4HTR2CHTR2B | |
| SCHEMBL31471369 | 0.80 | GRIN1 (0.48) | SLC6A4GRIN1GRIN2B | |
| SCHEMBL28400681 | 0.80 | SLC6A4 (0.36) | PDE2ASCN8ASCN10ASLC6A4HTR2C | |
| SCHEMBL27149063 | 0.77 | GRIN2B (0.45) | SCN8ASCN10AGRIN1GRIN2B | |
| SCHEMBL31071547 | 0.77 | HTR2C (0.49) | SLC6A4HTR2CHTR2BSLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689879-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-02-12 | — | — | EP | disclosed |
| CN-111148746-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-08-05 | — | — | CN | disclosed |
| US-11274101-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-11242348-B2 | — | — | 2022-02-08 | — | — | US | disclosed |
| US-20200255439-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-13 | — | — | US | disclosed |
| EP-3689879-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-08-05 | — | — | EP | disclosed |
| CN-111148746-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-05-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255439-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | PDE2A 2413/4885SCN8A 934/4885SCN10A 626/4885 |
| US-11274101-B2 | Heterocyclic compound | MAG, HTT, ACHE | PDE2A 2413/4885SCN8A 934/4885SCN10A 626/4885 |
| US-11242348-B2 | — | MAG, ACHE, GAP43 | PDE2A 1790/4885SCN8A 869/4885SCN10A 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.